FTC Gets Shot At Reviving AbbVie Pay-For-Delay Claims
The Federal Trade Commission can file for reconsideration of a decision to toss its pay-for-delay claims against AbbVie Inc. and Teva Pharmaceuticals USA Inc. over testosterone drug AndroGel, a Pennsylvania federal...To view the full article, register now.
Already a subscriber? Click here to view full article